[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"carboplatin\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:carboplatin":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,79,112],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100644426","prospective-observational-study-of-outcomes-after-gemcitabine-docetaxel-melphalan-and-carboplatin-with-autologous-stem-cell-transplantation-in-pediatric-relapsedrefractory-germ-cell-tumors-100644426",false,"NCT07662018","Prospective Observational Study of Outcomes After Gemcitabine, Docetaxel, Melphalan, and Carboplatin With Autologous Stem Cell Transplantation in Pediatric Relapsed\u002FRefractory Germ Cell Tumors","Inclusion Criteria\n\n* Male or female participants, greater than 1 month of age up to 21 years old. Neonates (birth to 1 month of age) will not be enrolled on this protocol.\n* Participants with relapsed\u002Frefractory seminomatous or nonseminomatous GCT who undergo an autologous stem cell transplantation (ASCT) with conditioning therapy including gemcitabine, docetaxel, melphalan, carboplatin (GemDMC) for germ cell tumors\n* As part of our analysis, we will also include participants aged 0-21 years old who have previously underwent ASCT with GemDMC\n* Participants who receive the following regimen:\n\nHigh dose chemotherapy (HDC) course #1:\n\nGemcitabine\u002FDocetaxel\u002FMelphalan\u002FCarboplatin D-6 Admission and start hydration D-5 Gemcitabine 1,500 mg\u002Fm2 IV Docetaxel 275 mg\u002Fm2 IV D-4 Gemcitabine 1,500 mg\u002Fm2 IV Melphalan 20 mg\u002Fm2 IV Carboplatin 250 mg\u002Fm2 IV D-3 Gemcitabine 1,500 mg\u002Fm2 IV Melphalan 20 mg\u002Fm2 IV Carboplatin 250 mg\u002Fm2 IV D-2 Gemcitabine 1,500 mg\u002Fm2 IV Melphalan 20 mg\u002Fm2 IV Carboplatin 250 mg\u002Fm2 IV D-1 Rest D0 Stem Cell infusion\n\nFollowed by HDC course #2 consisting of:\n\nHigh-dose course #2: Carboplatin\u002FEtoposide D-6 Admission and start hydration D-5 to -3 Etoposide 750 mg\u002Fm2 IV Carboplatin 700 mg\u002Fm2 IV D-2 Rest D-1 Rest D0 Stem Cell infusion\n\nExclusion Criteria\n\n* Participants who do not or did not receive GemDMC as part of the conditioning regimen for an ASCT are not eligible for this study","ALL","21 Years",{"count":18,"type":19},30,"ESTIMATED","OBSERVATIONAL","To collect information about treatment outcomes in pediatric and adolescent patients with relapsed\u002Frefractory germ cells tumors who receive GemDMC with an ASCT.",[23,24,25,26,27,28,29,30],"Prospective Observational Study","Gemcitabine","Docetaxel","Melphalan","Carboplatin","Stem Cell Transplantation","Pediatric Relapsed","Refractory Germ","RECRUITING","2026-06-17",{"date":34,"type":35},"2026-06-23","ACTUAL",{"date":37,"type":35},"2026-06-05",{"date":39,"type":19},"2033-12-31",{"name":41,"class":42},"M.D. Anderson Cancer Center","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":15,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":43},"100503480","phase-2-intratumoral-gemcitabine-paclitaxel-carboplatine-and-intravenous-nivolumab-for-locally-recurrence-of-head-and-neck-cancers-100503480","NCT05835804","Intratumoral Gemcitabine, Paclitaxel, Carboplatine and Intravenous Nivolumab for Locally Recurrence of Head and Neck Cancers","NIVOCHIMLOC","Inclusion Criteria:\n\n* WHO status : 0, 1 or 2.\n* Age \\> 18ans\n* Locally recurrence of a histologically-proven SCCHN after failure of conventional treatments (surgery, radiotherapy, chemotherapy with platinum compounds, cetuximab)\n* Nivolumab treatment in second line encouring according to AMM but with insufficient efficacy\n* Possible location of the tumour by clinical examination, CT-scan\n* Metastases are admitted if there is no vital prognoses threaten and if a clinical benefit is expected by treating local recurrence.\n* Neutrophils \\> 1000\u002Fmm3.\n* Platelets \\> 100 000\u002Fmm3.\n* Blood créatinine \\\u003C 15 mg\u002FL. Blood bilirubine \\\u003C 30 mg\u002FL\n* Prothrombin rate \\> 70 %.\n* Social insurance\n* Informed consent\n\nExclusion Criteria:\n\n* WHO status : 0, 1 or 2.\n* Age \\> 18ans\n* Locally recurrence of a histologically-proven SCCHN after failure of conventional treatments (surgery, radiotherapy, chemotherapy with platinum compounds, cetuximab)\n* Nivolumab treatment in second line encouring according to AMM but with insufficient efficacy\n* Possible location of the tumour by clinical examination, CT-scan\n* Metastases are admitted if there is no vital prognoses threaten and if a clinical benefit is expected by treating local recurrence.\n* Neutrophils \\> 1000\u002Fmm3.\n* Platelets \\> 100 000\u002Fmm3.\n* Blood créatinine \\\u003C 15 mg\u002FL. Blood bilirubine \\\u003C 30 mg\u002FL\n* Prothrombin rate \\> 70 %.\n* Social insurance\n* Informed consent","18 Years",{"count":53,"type":19},39,"INTERVENTIONAL",[56],"PHASE2","Patients with locally recurrent squamous-cell carcinoma of the head and neck (SCCHN) after Chemotherapy and immunotherapy have a very poor prognosis and limited therapeutic options.\n\nIntratumoral chemotherapy (ITC) with cisplatin and epinephrine in order to increase the local cisplatin retention lead to a 50 % response rate in several studies but was given up due to the poor local tolerance with frequent necrosis of the peritumoral tissues. Gemcitabine, carboplatin and paclitaxel (GCP) are used in advanced SCCHN. These chemotherapies seem to be interesting options for intratumoral infusion: their different effect could lead to avoid chemotherapy resistance with a good tolerance profile, without tissue necrosis profile. The other major option for recurrent SCCHN is immunotherapy by Nivolumab, an anti PD-1 with a 13% mediane response rate. Nevertheless, the failure of this treatment stay unclear, but immunosuppressive action of the tumour is suspected. The presence of tumoral antigen could lead to better response to immunotherapy; association of chemotherapy and immunotherapy seems a promosing association to avoid treatment resistance as cytotoxic release tumoral antigen; it could also be associated to an abscopal effect.\n\nThe aim of the study is to evaluate the efficacy of ITC using GCP in LOCAL recurrent SCCHN treated by nivolumab.",[59,60,27,61],"Squamous Cell Carcinoma of the Head and Neck","Paclitaxel","Nivolumab",[59,63,64,65,66,67,68],"local reccurence of malignant tumor","intrumoral chemotherapy","gemcitabin","paclitaxel","carboplatin","nivolumab","NOT_YET_RECRUITING","2025-03-18",{"date":72,"type":35},"2025-03-21",{"date":74,"type":19},"2025-11",{"date":76,"type":19},"2027-04",{"name":78,"class":42},"Centre Hospitalier Universitaire, Amiens",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":15,"minAge":51,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":54,"phases":88,"briefSummary":89,"conditions":90,"keywords":98,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":43},"100574161","phase-2-neoadjuvant-befotertinib-combined-bevacizumab-or-platinum-based-double-chemotherapy-for-resectable-locally-advanced-egfr-mutation-positive-non-small-cell-lung-cancer-100574161","NCT06755684","Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer","Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer: a Single-center, Randomized Controlled Trial","Inclusion Criteria:\n\n* NSCLC patient with EGFR sensitive mutation as confirmed by needle biopsy;\n* At stage II-IIIA (TNM Staging, Version 8) as identified by chest CT, PET-CT or\u002Fand EBUS;\n* No systemic metastasis (confirmed by head MRI, whole body bone scan, PET-CT, liver and adrenal CT, etc.);\n* With the feasibility to receive radical surgery ;\n* Good lung function that could tolerate surgical treatment;\n* Aged 18-75 years;\n* At least one measurable tumor foci (the longest diameter measured by CT shall be \\> 10 mm);\n* Other major organs shall function well (liver, kidney, blood system, etc.):\n* ECOG PS score shall be 0-1;\n* The child-bearing female must undergo pregnancy test within 7 days before starting the treatment and the result shall be negative. Reliable contraceptive measures, such as intrauterine device, contraceptive pill and condom, shall be adopted during the trial and within 30 days after completion of the trial. The child-bearing male shall use condom for contraception during the trial and within 30 days after completion of the trial;\n* The patient shall sign the Informed Consent Form.\n\nExclusion Criteria:\n\n* The patient has undergone any systemic anti-cancer treatment for NSCLC, including surgical treatment, local radiotherapy, cytotoxic drug treatment, targeted drug treatment and experimental treatment, etc.;\n* The patient suffers from any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina pectoris, angina pectoris that starts to attack within the last 3 months, congestive heart failure \\[≥ Grade II specified by New York Heart Association (NYHA)\\], cardiac infarction (6 months before enrollment), severe arrhythmia and liver, kidney or metabolic diseases that requires drug treatment;\n* The patient is a carrier of HIV;\n* The patient has had or is currently suffering from interstitial lung disease;\n* The patient had undergone other major systemic operations or suffered from severe trauma within 3 months before the trial;\n* The patient is allergic to befotertinib or its any excipients;\n* The patient is allergic to bevacizumab or its any excipients;\n* The patient is allergic to platinum-based double chemotherapy or its any excipients;\n* The female patient is in pregnancy or lactation period;\n* There are any conditions under which the investigator considers the patient is not suitable to be enrolled.",{"count":87,"type":19},60,[56],"This study targeted patients with resectable stage II-IIIA non-small cell lung cancer with EGFR mutation",[91,92,93,94,27,95,96,97],"EGFR","Non-Small Cell Lung Cancer","Locally Advanced Non-Small Cell Lung Cancer","Pemetrexed","Bevacizumab","Antineoplastic Agents","Tyrosine Kinase Inhibitor",[99,100,101,95,102],"EGFR-TKI","NSCLC","Chemotherapy","Locally advanced non-small cell lung cancer","2025-01-03",{"date":105,"type":35},"2025-01-06",{"date":107,"type":35},"2024-11-07",{"date":109,"type":19},"2028-12-31",{"name":111,"class":42},"Peng Zhang",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":15,"minAge":51,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":54,"phases":122,"briefSummary":124,"conditions":125,"keywords":128,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":43},"100356327","phase-3-cisplatin-based-and-carboplatin-based-chemoradiation-in-locoregionally-advanced-nasopharyngeal-carcinoma-100356327","NCT03919552","Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma","Intensity-modulated Radiation Therapy Combined With Cisplatin-based or Carboplatin-based Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma：: A Phase 3 Trial","Inclusion Criteria:\n\n* Patients with newly histologically confirmed non-keratinizing (according to World Health Organization (WHO) histologically type).\n* Tumor staged as T3-4Nx\u002FTxN2-3 (according to the 8th American Joint Commission on Cancer edition).\n* No evidence of distant metastasis (M0).\n* Satisfactory performance status: Karnofsky scale (KPS) \\> 70.\n* Adequate marrow: leucocyte count ≥4000\u002FμL, hemoglobin ≥90g\u002FL and platelet count ≥100000\u002FμL.\n* Normal liver function test: Alanine Aminotransferase (ALT)、Aspartate Aminotransferase (AST) \\\u003C1.5×upper limit of normal (ULN) concomitant with alkaline phosphatase (ALP) ≤2.5×ULN, and bilirubin ≤ULN.\n* Adequate renal function: creatinine clearance ≥60 ml\u002Fmin.\n* Patients must be informed of the investigational nature of this study and give written informed consent.\n\nExclusion Criteria:\n\n* WHO Type keratinizing squamous cell carcinoma or basaloid squamous cell carcinoma.\n* Age ≥65 years or \\\u003C18 years.\n* Treatment with palliative intent.\n* Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer.\n* Pregnancy or lactation.\n* History of previous radiotherapy (except for non-melanomatous skin cancers outside intended RT treatment volume).\n* Prior chemotherapy or surgery (except diagnostic) to primary tumor or nodes.\n* Any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose \\>1.5×ULN), and emotional disturbance.","64 Years",{"count":121,"type":19},482,[123],"PHASE3","The purpose of this study is to compare cisplatin-based with carboplatin-based chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma (NPC), in order to confirm the value of carboplatin-based chemoradiotherapy in NPC patients.",[126,27,127],"Cisplatin","NPC",[129,130,67],"Nasopharyngeal Carcinoma","cisplatin","2023-06-14",{"date":133,"type":35},"2023-06-18",{"date":135,"type":35},"2018-01-31",{"date":137,"type":19},"2026-12-31",{"name":139,"class":42},"Nanfang Hospital, Southern Medical University"]